Table 1 Clinical characteristics associated with PRAF2 mRNA expression
Characteristics | All patients | PRAF2 level | Overall survival | |||
|---|---|---|---|---|---|---|
Low | High | P value | mOS (95% CI) | P value | ||
Patients, No. | 77 | 41 | 36 | |||
Age, y | ||||||
≤ 60 | 34 | 16 | 18 | 0.366 | 28.0 (16.7–39.3) | 0.144 |
> 60 | 43 | 25 | 18 | 26.0 (17.0–35.0) | ||
Gender | ||||||
Males | 59 | 34 | 25 | 0.166 | 28.0 (22.2–33.8) | 0.234 |
Females | 18 | 7 | 11 | 22.0 (20.2–23.8) | ||
Location | ||||||
Up | 10 | 3 | 7 | 0.192 | 29.0 (13.4–38.6) | 0.624 |
Middle | 45 | 25 | 20 | 26.8 (19.5–34.0) | ||
Low | 22 | 13 | 9 | 30.0 (14.1–45.9) | ||
G stage | ||||||
G1 | 21 | 16 | 5 | 0.049* | 36.0 (20.1–33.9) | 0.009* |
G2 | 45 | 20 | 25 | 22.0 (11.1–32.9) | ||
G3 | 11 | 5 | 6 | 17.3 (12.3–22.4) | ||
TNM stage | ||||||
I | 4 | 4 | 0 | 0.009* | 25 | 0.010* |
II | 52 | 31 | 21 | 30.0 (23.7–36.3) | ||
III | 21 | 6 | 15 | 20.0 (15.2–24.8) | ||
PRAF2 level | ||||||
Low | 33.0 (24.2–41.8) | < 0.001* | ||||
High | 20.0 (16.3–23.6) | |||||